Recently, intestinal IL-33 promoted microbiota-derived trimethylamine N-oxide synthesis and accelerated MASLD progression, whereas global or intestinal deletion of Il33 in mice ameliorated metabolic disorders, inflammation, and fibrosis associated with MASLD [165]. Here, IL33 is linked to metabolic disease.